Prnewswire·2026-01-02 21:05Core Viewpoint - ADC Therapeutics SA has granted options to purchase 6,000 common shares to a new employee as an inducement for employment, aiming to motivate and reward high performance [1][2]. Group 1: Grant Details - The grant was approved by the Compensation Committee under the Company's Inducement Plan to encourage significant contributions to the Company's success [2]. - The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next three years, fully vesting by the fourth anniversary [3]. Group 2: Company Overview - ADC Therapeutics is a leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients through its portfolio, including ZYNLONTA [4]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [5]. - The company is also developing a next-generation PSMA-targeting ADC with a differentiated payload and novel linker [5]. Group 3: Company Operations - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, focusing on innovation in ADC development from clinical to commercialization [6].